- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
Phospho-ATG4D-S15 AntibodyPeptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP3394a | 0.1 mg 400 ul | In Stock | $ 120.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
Phospho-ATG4D-S15 Antibody - Product info | |
| Application | DB
|
| Primary Accession | Q86TL0 |
| Reactivity | Human |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 52922 Da |
Phospho-ATG4D-S15 Antibody - Additional info | |
| Gene ID 84971 | |
| Other Names ATG4D; APG4D; AUTL4; Cysteine protease ATG4D; AUT-like 4 cysteine endopeptidase; Autophagin-4; Autophagy-related cysteine endopeptidase 4; Autophagy-related protein 4 homolog D | |
| Target/Specificity This Phospho-ATG4D-S15 antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide between 1~30 amino acids surrounding S15 of human APG4D. Patent pending. | |
| Dilution DB~~1:500 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is first purified by protein A affinity chromatography. Then, the antibody fraction is peptide affinity purified in a 2-step procedure with peptides. The antibody is eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions Phospho-ATG4D-S15 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. | |
Phospho-ATG4D-S15 Antibody - Protein Information | |
| Name ATG4D | |
| Synonyms APG4D, AUTL4 | |
| Function Cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE)-conjugated form, and has the capacity for the binding to autophagosomes | |
| Cellular Location Cytoplasm (Probable). | |
| Tissue Location Mainly expressed in skeletal muscle and, to a lower extent, in testis | |
Phospho-ATG4D-S15 Antibody - Related products
AM1896a: ATG4D antibody (Ascites)
AP11448a: ATG4D Antibody (N-term)
AP1811a: ATG4D Antibody (N-term)
AP1811b: ATG4D Antibody (Center)
AP1811c: ATG4D Antibody (C-term)
AP1811e: ATG4D Antibody (C-term)
AP1811f: ATG4D Antibody (center)
AP3394a: Phospho-ATG4D-S15 Antibody
AP3395a: Phospho-ATG4D-S341 Antibody
AP3395b: Phospho-ATG4D-S467 Antibody
RI10457: ATG4D predesign siRNA
DC08667: Human ATG4D cDNA Clone
BP1811a: APG4D Antibody (N-term) Blocking Peptide
BP1811b: APG4D Antibody (Center) Blocking Peptide
BP1811c: APG4D Antibody (C-term) Blocking Peptide
BP1811e: APG4D Antibody (C-term) Blocking Peptide
BP1811f: ATG4D Antibody (center) Blocking Peptide
BP3394a: Phospho-APG4D-S15 Antibody Blocking Peptide
Phospho-ATG4D-S15 Antibody - Application data
-
Dot blot analysis of anti-Phospho-APG4D-pS15 Phospho-specific Pab (Cat.#AP3394a) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.
Phospho-ATG4D-S15 Antibody - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
APG4 is a cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE)-conjugated form, and has the capacity for the binding to autophagosomes. Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole).
REFERENCES
Baehrecke EH. Nat Rev Mol Cell Biol. 6(6):505-10. (2005) Lum JJ, et al. Nat Rev Mol Cell Biol. 6(6):439-48. (2005) Greenberg JT. Dev Cell. 8(6):799-801. (2005) Levine B. Cell. 120(2):159-62. (2005) Shintani T and Klionsky DJ. Science. 306(5698):990-5. (2004)